Halifax, N.S. (March 12, 2015) —STI Technologies Limited has been named one of Canada’s Best Managed Companies in 2014. Sponsored by Deloitte, CIBC, National Post, Queen’s School of Business and MacKay CEO Forums, this award recognizes Canadian-owned and -managed companies with revenues of over $10 million for sustained growth, financial performance and management practices.

“We’re thrilled and extremely proud to receive this national award of business excellence,” says STI Technologies CEO Tim Gillis. “Our people are focused on innovation and the delivery of programs to millions of Canadian patients. STI has seen consistent growth over the past few years and has expanded the company with diverse and talented people to meet the needs and expectations of our clients. Every member of our team should take ownership of this award.”

STI Technologies is a Halifax-based health-care technology company that provides Canadian patients with greater choice and broader access to the best medications and health-care products. Led by former CEO Steve Nicolle until the end of 2014, STI has seen sustained growth supporting the health-care system by delivering reimbursement, patient-engagement and patient-management solutions that improve health outcomes through partnerships with Canada’s top pharmaceutical companies.

By making its user-friendly solutions available online and through health-care providers across the country, STI is the leader in its industry, with millions of patients benefiting from its programs. Its free innoviCares patient-benefit plan is the ninth-largest private plan in Canada, covering nearly 100 medications and products from 20 drug manufacturers; to date, it has helped about 800,000 Canadians.

STI’s business model has adapted and evolved over the last 12 years as the company has gained a better understanding of the market challenges faced by its clients. “As we develop innovative products to meet our clients’ needs, we recognize that this sustained success will lead to improved patient engagement, adherence and continuity of care—and, ultimately, to better health outcomes for many Canadians,” says Gillis.

About Canada’s Best Managed Companies

Every year since the launch of the program in 1993, hundreds of entrepreneurial companies have competed for this designation in a rigorous and independent process that evaluates their management skills and practices. The awards are granted on four levels: Best Managed winner; Requalified member; Gold Standard winner; and Platinum Club member. For more information, visit bestmanagedcompanies.ca.

For more information, please contact:

Erin Solomon, marketing associate
STI Technologies Limited, smartsti.com
(902) 442-2071
, (902) 877-1849
, This email address is being protected from spambots. You need JavaScript enabled to view it.

 

innovicares-bday-graphicsHalifax, N.S. (Jan. 26, 2014) — STI Technologies Limited is marking two years of helping Canadian patients have greater access to medications through its free innoviCares patient-benefit plan. The innoviCares plan includes many types of benefits, such as allowing patients to receive brand-name medications and health-care products at an equal or similar price to the generic alternatives.

When the plan launched, 12 medications were covered; today innoviCares is the ninth-largest private plan in Canada, and covers nearly 100 medications and products from 20 drug manufacturers. There are no monthly fees, and the innoviCares card has been accepted at over 98 per cent of Canadian pharmacies.

"Our innoviCares plan continues to grow," says Tim Gillis, chief executive officer at STI. "We're adding more tools, resources and benefits for patients to help patients manage their medications."

To date, the innoviCares card has helped nearly 800,000 Canadians, with over 50,000 benefitting from the plan each week. In addition to covering such well-known medications as Crestor, Ezetrol, Imovane, and Cipralex, innoviCares also offers free benefits towards such products as diabetes blood-glucose meters and test strips. "The innoviCares plan improves patients' medication choices," says Gillis. "The stress that people are under to be able to afford certain medications is huge. We're here to help them with that."

Partnering pharmaceutical companies believe that greater access and patient choice to the most effective medications helps lead to better health outcomes. "With this in mind, we've added 14 Sanofi products to the innoviCares plan to ensure patient access to brand-name medications prescribed by their physician", says Tracey Ramsay, Sanofi Canada's Vice President of Hospital, Specialty and Consumer Health.

STI Technologies Limited is the largest intelligent reimbursement solutions provider to the Canadian healthcare industry, implementing innovative programs on behalf of major pharmaceutical companies. Using their advanced patient-centric technology platform, all of the Halifax-based company's programs, support greater access and choice to medications and health-care products to improve patient outcomes. Visit smartsti.com to learn more.

For more information, please contact:
Erin Solomon, marketing associate
STI Technologies Limited
(902) 442-2071
 and (902) 877-1849
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

STI Technologies ranks No. 5 on Progress magazine’s 2014 Fastest Growing Companies list

Halifax, N.S. (Dec. 2, 2014) — Progress magazine has ranked STI Technologies Limited No. 5 on its 2014 Fastest Growing Companies list. Now in its 15th year, the list is a highly anticipated ranking of Atlantic Canadian companies that have reported the most significant increase in revenues over the past three years. These companies are setting the pace for the new economy, not just regionally but also nationally.

In 2011 STI Technologies Limited was ranked No. 24 of all companies, with a 37% three-year growth rate. Last year it was No. 7 of companies with less than $25 million revenue, with an 83% growth rate. In 2013 the company was again No. 7, with an impressive 113% growth rate.

“I give the credit for our continued growth to our people,” said incoming CEO Tim Gillis, the former CFO and VP operations. “In 2014 we made several new hires, including at the senior level, which allowed us to deepen our relationships with our clients so they could better see our overall level of sophistication and capabilities. To maintain a growth trajectory in the future, we plan on continued technology and marketing investment, all the time spreading the word about STI and how our programs lead to healthier Canadians.”

STI Technologies Limited connects physicians, patients, pharmacy and pharmaceutical companies with a variety of intelligent reimbursement and data programs that ultimately improve patient outcomes. The Halifax-based company facilitates valuable interactions between each of these four distinct groups, using an advanced patient-centric technology platform to power all of its solutions. Visit smartsti.com to learn more.

The Fastest Growing Companies come from a wide array of sectors. The ones reporting the most rapid growth are in innovation, IT, aerospace and defence, ocean technology and hospitality. “Even companies that are experiencing 40% growth are showing us that a spike in sales in possible, even in challenging markets,” says Progress publisher Neville Gilfoy. Visit progressmedia.ca to learn more.

For more information, please contact:
Erin Solomon, marketing associate
STI Technologies Limited
(902) 442-2071
 and (902) 877-1849

This email address is being protected from spambots. You need JavaScript enabled to view it.

Gillis to Succeed Nicolle as Chief Executive Officer of STI Technologies Limited

Halifax, Nova Scotia, Canada (October 31, 2014)

Steve Nicolle, CEO of STI Technologies Limited (STI) will be stepping down from his role at the end of the year. Effective January 1, 2015, Tim Gillis will be succeeding Mr. Nicolle, who will continue to serve on the Company’s Board of Directors.

Having worked for STI since 2010, Gillis currently holds the positions of Chief Financial Officer and Vice President of Operations. “Tim has worked closely with me for the past 4 years and knows the business extremely well. Together we completed one of the largest investments in the region with a $17M investment from Imperial Capital Group in 2013,” said Mr. Nicolle.

Nicolle has been CEO of STI since 2010 and has overseen the Company’s significant growth from a local start-up to one of Canada’s leading healthcare IT companies. “Under Steve’s leadership, STI’s revenue has grown by over 500%, and the company has been recognized for four consecutive years as one of the Best Companies to Work in Atlantic Canada,” said Mr. Gillis.

Diagnosed with Multiple Sclerosis in 2012, Nicolle is passionate about the patient support programs that STI creates for pharmaceutical companies. “Now being one of 100,000 Canadians with MS, I appreciate first-hand how important it is to have access to the best medications available”, said Nicolle, “My MS was a catalyst for the timing of this decision but the transition of leadership to Tim Gillis was planned well before my diagnosis.”

Formerly, Gillis held senior positions with a number of successful companies including Stantec, Ernst & Young, Clarke Inc., and Clear Picture Corporation and has been active in our community as a former board member of Halifax’s United Way for nearly 10 years. “We build the most innovative programs to connect patients to their health care and medications,” said Gillis, “The future of the Company is to build on these initiatives with our pharmaceutical partners; further improving health care in Canada – one patient at a time.”

“Tim’s credentials speak for themselves. He is the right person to take STI to the next level”, said Justin MacCormack, head of Healthcare Investing for Imperial Capital and a member of STI’s Board of Directors.

 

Contact:
Erin Solomon, Marketing Associate
Tel: (902) 442-2071
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About STI Technologies Limited
STI Technologies Limited is the largest intelligent reimbursement solutions provider to the Canadian healthcare industry, implementing innovative programs on behalf of major pharmaceutical companies. STI’s flagship solution, innoviCares, is a free supplementary benefit plan that provides coverage for nearly 100 medications and healthcare products, providing patients with greater choice and access. InnoviCares covers up to the difference in cost between many brand-name medications and their generic alternatives.

www.smartsti.com

www.innovicares.ca  

 

Choice in Medications Improves Patient Outcomes

HALIFAXMay 15, 2014 /CNW/ - InnoviCares, Canada's only free multi-drug manufacturer patient benefit plan, marked their 600,000 member on April 28, 2014, and their participation rates show signs of acceleration through increasing partnerships and widespread patient satisfaction.

"We are extremely pleased with the growth of innoviCares. Since its launch in January 2013, innoviCares has already grown to bring together 18 different drug manufacturers and nearly 100 products covered," said Steve Nicolle, CEO of STI Technologies Ltd, innoviCares parent company. "By complementing public and private drug plans through greater access to original brand name medications, we are improving health outcomes and adherence rates for many patients, and at no additional cost to them."

Employers, associations, physicians, and pharmacists have widely embraced the program, and for countless patients innoviCares offers significant financial savings and stability in their healthcare.

STI Technologies Limited was recently visited by Troy Wellington, an innoviCares member from Barrie, Ontario, who stressed the positive impact that the plan has had in his family's life. "You don't think that something so small could make such a big, drastic change in a person's life, but it did. Emotionally stable, mentally stable, physically stable... The financial burden was lifted from my wife's shoulders for those medications."

InnoviCares supports a patient's choice to remain on original brand name medication by paying towards the cost difference between brand and the generic alternative.

"Reaching out for medical assistance when a person has reasons to believe they may be experiencing mental health concerns is extremely important," says Dave Gallson, Associate National Executive Director for Moods Disorders Society of Canada. "Working with your Doctor or healthcare professional, proper diagnosis and a care plan which often includes finding the appropriate medication can make a significant impact in a patient's continued health and well-being.  Thanks to innoviCares, patients have access to brand medication at the same price of a generic."

To view "Troy's Story" visit:
https://www.youtube.com/watch?v=_n8OmfvIY7I

For more information visit
www.innovicares.ca
www.mooddisorderscanada.ca

SOURCE STI Technologies Limited

Video with caption: "Video: Diagnosed with Bipolar Schizoaffective disorder in 2010, Troy Wellington could no longer afford the out-of-pocket costs for his prescribed medication that had him stabilized, despite facing side effects from the alternate medication covered by his insurance plan. His psychiatrist then introduced him to innoviCares, Canada's only free patient benefit plan, which supports a patient's choice by paying up to the difference between original brand and the generic alternative.". 

Image with caption: "Troy & Sheri Wellington were faced with choosing between medical stability and financial stability until InnoviCares, Canada's only free patient benefit plan, paid the difference between the original brand medication and the generic alternative. (CNW Group/STI Technologies Limited)". Image available at:http://photos.newswire.ca/images/download/20140515_C8225_PHOTO_EN_40339.jpg

 For further information:

Erin Solomon, Marketing Associate, STI
Tel: 902-442-2071
This email address is being protected from spambots. You need JavaScript enabled to view it.

About STI Technologies Limited
www.smartsti.com

 

Page 1 of 8

What's Happening

plavix.jpg